Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aldoxorubicin vs Topotecan in Metastatic SCLC
NCT02200757Phase 2Completed
- Sponsor
- ImmunityBio, Inc.
- Start
- Apr 2015
- Primary completion
- May 2017
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of aldoxorubicin in small cell lung cancer (SCLC), sponsored by ImmunityBio, Inc.. Started Apr 2015; status: completed.
02
Drugs
aldoxorubicin
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT02200757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02200757.